Eli Lilly and Company: Cardiovascular Diseases trials
The registry lists 15 Cardiovascular Diseases studies with Eli Lilly and Company as lead sponsor. 5 are open to participants now and 5 have results posted.
Phase 1 2Phase 2 4Phase 3 8No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular RiskNot yet recruitingNCT07900633Phase 3
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseaseRecruitingNCT07839936Phase 2
- A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventRecruitingNCT07783802Phase 2
- A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High RiskRecruitingNCT07613294Phase 3
- Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular DiseaseEnrolling by invitationNCT06112327
- A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular EventsCompletedNCT05563246Phase 2Results posted
- A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy ParticipantsCompletedNCT01825889Phase 1Results posted
- A Study of Evacetrapib in High-Risk Vascular DiseaseTerminatedNCT01687998Phase 3Results posted
- Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)CompletedNCT01394952Phase 3Results posted
- A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)CompletedNCT00059215Phase 2Results posted
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Active, not recruitingNCT06383390Phase 3
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseCompletedNCT05882045Phase 3
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskCompletedNCT05803421Phase 3
- A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular DiseaseCompletedNCT05398029Phase 1
- Raloxifene Use for The HeartCompletedNCT00190593Phase 3